

# Chlorpheniramine reduces COVID-19 risk: real-time meta analysis of 3 studies

@CovidAnalysis, July 2025, Version 1  
<https://c19early.org/cpmmeta.html>

## Abstract


Significantly lower risk is seen for recovery. 2 studies (both from the same team/sponsor) show significant benefit.

Meta analysis using the most serious outcome reported shows 56% [46-64%] lower risk. Results are similar for Randomized Controlled Trials and better for peer-reviewed studies.


Currently there is limited data, with only 806 patients and only 2 control events for the most serious outcome in trials to date. Studies to date are from only 2 different groups.

No treatment is 100% effective. Protocols combine safe and effective options with individual risk/benefit analysis and monitoring. Chlorpheniramine may affect the natural microbiome, especially with prolonged use. All data and sources to reproduce this analysis are in the appendix.


## Serious Outcome Risk



## Chlorpheniramine for COVID-19 c19early.org July 2025



## 100% Evolution of COVID-19 clinical evidence c19early.org July 2025




## CHLORPHENIRAMINE FOR COVID-19 — HIGHLIGHTS

Chlorpheniramine reduces risk with very high confidence for pooled analysis, low confidence for recovery, and very low confidence for hospitalization.


45th treatment shown effective in December 2022, now with  $p < 0.00000000001$  from 3 studies.

Real-time updates and corrections with a consistent protocol for 172 treatments. Outcome specific analysis and combined evidence from all studies including treatment delay, a primary confounding factor.

### 3 chlorpheniramine COVID-19 studies

c19early.org  
July 2025

### Timeline of COVID-19 chlorpheniramine studies (pooled effects)


c19early.org  
July 2025

**Figure 1. A. Random effects meta-analysis.** This plot shows pooled effects, see the specific outcome analyses for individual outcomes. Analysis validating pooled outcomes for COVID-19 can be found [below](#). Effect extraction is pre-specified, using the most serious outcome reported. For details see the [appendix](#). **B. Timeline of results in chlorpheniramine studies.** The marked date indicates the time when efficacy was known with a statistically significant improvement of  $\geq 10\%$  from  $\geq 3$  studies for pooled outcomes.

## Introduction

### Immediate treatment recommended

SARS-CoV-2 infection typically starts in the upper respiratory tract, and specifically the nasal respiratory epithelium. Entry via the eyes and gastrointestinal tract is possible, but less common, and entry via other routes is rare. Infection may progress to the lower respiratory tract, other tissues, and the nervous and cardiovascular systems. The primary initial route for entry into the central nervous system is thought to be the olfactory nerve in the nasal cavity<sup>2</sup>. Progression may lead to cytokine storm, pneumonia, ARDS, neurological injury<sup>3-15</sup> and cognitive deficits<sup>6,11</sup>, cardiovascular complications<sup>16-20</sup>, organ failure, and death. Even mild untreated infections may result in persistent cognitive deficits<sup>21</sup>—the spike protein binds to fibrin leading to fibrinolysis-resistant blood clots, thromboinflammation, and neuropathology. Systemic treatments may be insufficient to prevent neurological damage<sup>10</sup>. Minimizing replication as early as possible is recommended.




**Figure 2. SARS-CoV-2 spike protein fibrin binding leads to thromboinflammation and neuropathology, from<sup>1</sup>.**

### Targeted treatment to the primary location of initial infection

Logically, stopping replication in the upper respiratory tract should be simpler and more effective. *Wu et al.*, using an airway organoid model incorporating many *in vivo* aspects, show that SARS-CoV-2 initially attaches to cilia—hair-like structures responsible for moving the mucus layer and where ACE2 is localized in nasal epithelial cells<sup>24</sup>. The mucus layer and the need for ciliary transport slow down infection, providing more time for localized treatments<sup>22,23</sup>. Early or prophylactic nasopharyngeal/oropharyngeal treatment may avoid the consequences of viral replication in other tissues, and avoid the requirement for systemic treatments with greater potential for side effects.

Many treatments are expected to modulate infection

SARS-CoV-2 infection and replication involves the complex interplay of 100+ host and viral proteins and other factors<sup>A,25-32</sup>, providing many therapeutic targets for which many existing compounds have known activity. Scientists have predicted that over 9,000 compounds may reduce COVID-19 risk<sup>33</sup>, either by directly minimizing infection or replication, by supporting immune system function, or by minimizing secondary complications.




**Figure 3.** SARS-CoV-2 virions attached to cilia of nasal epithelial cells, from Chien-Ting Wu<sup>22,23</sup>.

Analysis

We analyze all significant controlled studies of chlorpheniramine for COVID-19. Search methods, inclusion criteria, effect extraction criteria (more serious outcomes have priority), all individual study data, PRISMA answers, and statistical methods are detailed in Appendix 1. We present random effects meta-analysis results for all studies, individual outcomes, peer-reviewed studies, and Randomized Controlled Trials (RCTs).

Treatment timing

Figure 4 shows stages of possible treatment for COVID-19. Prophylaxis refers to regularly taking medication before becoming sick, in order to prevent or minimize infection. Early Treatment refers to treatment immediately or soon after symptoms appear, while Late Treatment refers to more delayed treatment. Currently all chlorpheniramine studies use early treatment.



**Figure 4.** Treatment stages.

Preclinical Research

An *In Vitro* study supports the efficacy of chlorpheniramine<sup>34</sup>.

Preclinical research is an important part of the development of treatments, however results may be very different in clinical trials. Preclinical results are not used in this paper.

Results


Table 1 summarizes the results for all studies, for Randomized Controlled Trials, for peer-reviewed studies, and for specific outcomes. Figure 5, 6, 7, 8, and 9 show forest plots for random effects meta-analysis of all studies with pooled effects, hospitalization, recovery, peer reviewed studies, and long COVID.

	Relative Risk	Studies	Patients
All studies	<b>0.44</b> [0.36-0.54] ****	3	806
Peer-reviewed	<b>0.13</b> [0.01-2.46]	1	45
RCTs	<b>0.37</b> [0.23-0.61] ****	2	146
Recovery	<b>0.44</b> [0.36-0.55] ****	2	761

**Table 1.** Random effects meta-analysis for all studies, for Randomized Controlled Trials, for peer-reviewed studies, and for specific outcomes. Results show the relative risk with treatment and the 95% confidence interval. \*\*\*\*  $p < 0.0001$ .

### 3 chlorpheniramine COVID-19 studies


c19early.org  
July 2025



**Figure 5.** Random effects meta-analysis for all studies. This plot shows pooled effects, see the specific outcome analyses for individual outcomes. Analysis validating pooled outcomes for COVID-19 can be found below. Effect extraction is pre-specified, using the most serious outcome reported. For details see the appendix.

### 1 chlorpheniramine COVID-19 hospitalization result


c19early.org  
July 2025



**Figure 6.** Random effects meta-analysis for hospitalization.

## 2 chlorpheniramine COVID-19 recovery results


c19early.org  
July 2025



**Figure 7. Random effects meta-analysis for recovery.**

## 1 chlorpheniramine COVID-19 peer reviewed studies

c19early.org  
July 2025




**Figure 8. Random effects meta-analysis for peer reviewed studies.** Effect extraction is pre-specified, using the most serious outcome reported, see the appendix for details. Analysis validating pooled outcomes for COVID-19 can be found below.

Zeraatkar et al. analyze 356 COVID-19 trials, finding no significant evidence that preprint results are inconsistent with peer-reviewed studies. They also show extremely long peer-review delays, with a median of 6 months to journal publication. A six month delay was equivalent to around 1.5 million deaths during the first two years of the pandemic. Authors recommend using preprint evidence, with appropriate checks for potential falsified data, which provides higher certainty much earlier.

Davidson et al. also showed no important difference between meta analysis results of preprints and peer-reviewed publications for COVID-19, based on 37 meta analyses including 114 trials.

## 1 chlorpheniramine COVID-19 long COVID result


c19early.org  
July 2025



**Figure 9. Random effects meta-analysis for long COVID.** Effect extraction is pre-specified, using the most serious outcome reported, see the appendix for details. Analysis validating pooled outcomes for COVID-19 can be found below.

## Randomized Controlled Trials (RCTs)

Figure 10 shows a comparison of results for RCTs and observational studies. Random effects meta analysis of RCTs shows 63% improvement, compared to 54% for other studies. Figure 11 shows a forest plot for random effects meta-analysis of all Randomized Controlled Trials. RCT results are included in Table 1.



**Figure 10.** Results for RCTs and observational studies.

### RCTs have many potential biases

RCTs help to make study groups more similar and can provide a higher level of evidence, however they are subject to many biases<sup>37</sup>, and analysis of double-blind RCTs has identified extreme levels of bias<sup>38</sup>. For COVID-19, the overhead may delay treatment, dramatically compromising efficacy; they may encourage monotherapy for simplicity at the cost of efficacy which may rely on combined or synergistic effects; the participants that sign up may not reflect real world usage or the population that benefits most in terms of age, comorbidities, severity of illness, or other factors; standard of care may be compromised and unable to evolve quickly based on emerging research for new diseases; errors may be made in randomization and medication delivery; and investigators may have hidden agendas or vested interests influencing design, operation, analysis, reporting, and the potential for fraud. All of these biases have been observed with COVID-19 RCTs. There is no guarantee that a specific RCT provides a higher level of evidence.

### Conflicts of interest for COVID-19 RCTs

RCTs are expensive and many RCTs are funded by pharmaceutical companies or interests closely aligned with pharmaceutical companies. For COVID-19, this creates an incentive to show efficacy for patented commercial products, and an incentive to show a lack of efficacy for inexpensive treatments. The bias is expected to be significant, for example *Als-Nielsen et al.* analyzed 370 RCTs from Cochrane reviews, showing that trials funded by for-profit organizations were 5 times more likely to recommend the experimental drug compared with those funded by nonprofit organizations. For COVID-19, some major philanthropic organizations are largely funded by investments with extreme conflicts of interest for and against specific COVID-19 interventions.

### RCTs for novel acute diseases requiring rapid treatment

High quality RCTs for novel acute diseases are more challenging, with increased ethical issues due to the urgency of treatment, increased risk due to enrollment delays, and more difficult design with a rapidly evolving evidence base. For COVID-19, the most common site of initial infection is the upper respiratory tract. Immediate treatment is likely to be most successful and may prevent or slow progression to other parts of the body. For a non-prophylaxis RCT, it makes sense to provide treatment in advance and instruct patients to use it immediately on symptoms, just as some governments have done by providing medication kits in advance. Unfortunately, no RCTs have been done in this way. Every treatment RCT to date involves delayed treatment. Among the 172 treatments we have analyzed, 67% of RCTs involve very late treatment 5+ days after onset. No non-prophylaxis COVID-19 RCTs match the potential real-world use of early treatments. They may more accurately represent results for treatments that require visiting a medical facility, e.g., those requiring intravenous administration.

### Observational studies have been shown to be reliable


Evidence shows that observational studies can also provide reliable results. *Concato et al.* found that well-designed observational studies do not systematically overestimate the magnitude of the effects of treatment compared to RCTs. *Anglemyer et al.* analyzed reviews comparing RCTs to observational studies and found little evidence for significant differences in effect estimates. We performed a similar analysis across the 172 treatments we cover,

showing no significant difference in the results of RCTs compared to observational studies, RR 0.98 [0.92-1.05]<sup>43</sup>. Similar results are found for all low-cost treatments, RR 1.00 [0.91-1.09]. High-cost treatments show a non-significant trend towards RCTs showing greater efficacy, RR 0.92 [0.84-1.02]. Details can be found in the supplementary data.

Lee (B) et al. showed that only 14% of the guidelines of the Infectious Diseases Society of America were based on RCTs. Evaluation of studies relies on an understanding of the study and potential biases. Limitations in an RCT can outweigh the benefits, for example excessive dosages, excessive treatment delays, or remote survey bias may have a greater effect on results. Ethical issues may also prevent running RCTs for known effective treatments. For more on issues with RCTs see<sup>45,46</sup>.

## RCT vs. observational from 5,918 studies

c19early.org Jul 2025



**Figure 12.** For COVID-19, observational study results do not systematically differ from RCTs, RR 0.98 [0.92-1.05] across 172 treatments<sup>40</sup>.

## Using all studies identifies efficacy 8+ months faster (9+ months for low-cost treatments)


Currently, 55 of the treatments we analyze show statistically significant efficacy or harm, defined as  $\geq 10\%$  decreased risk or  $>0\%$  increased risk from  $\geq 3$  studies. Of these, 58% have been confirmed in RCTs, with a mean delay of 7.7 months (64% with 8.9 months delay for low-cost treatments). The remaining treatments either have no RCTs, or the point estimate is consistent.

## Summary

We need to evaluate each trial on its own merits. RCTs for a given medication and disease may be more reliable, however they may also be less reliable. For off-patent medications, very high conflict of interest trials may be more likely to be RCTs, and more likely to be large trials that dominate meta analyses.

## 2 chlorpheniramine COVID-19 Randomized Controlled Trials

c19early.org  
July 2025




**Figure 11.** Random effects meta-analysis for all Randomized Controlled Trials. This plot shows pooled effects, see the specific outcome analyses for individual outcomes. Analysis validating pooled outcomes for COVID-19 can be found below. Effect extraction is pre-specified, using the most serious outcome reported. For details see the appendix.



## Application

In addition to the dosage and frequency of administration, efficacy for nasopharyngeal/oropharyngeal treatments may depend on many other details. For example considering sprays, viscosity, mucoadhesion, sprayability, and application angle are important.

Akash *et al.* performed a computational fluid dynamics study of nasal spray administration showing 100x improvement in nasopharyngeal drug delivery using a new spray placement protocol, which involves holding the spray nozzle as horizontally as possible at the nostril, with a slight tilt towards the cheeks. The study also found the optimal droplet size range for nasopharyngeal deposition was ~7-17 $\mu$ m.



**Figure 13.** Optimal spray angle may increase nasopharyngeal drug delivery 100x for nasal sprays, adapted from Akash *et al.*

## Heterogeneity

Heterogeneity in COVID-19 studies arises from many factors including:

### Treatment delay


The time between infection or the onset of symptoms and treatment may critically affect how well a treatment works. For example an antiviral may be very effective when used early but may not be effective in late stage disease, and may even be harmful. Oseltamivir, for example, is generally only considered effective for influenza when used within 0-36 or 0-48 hours<sup>48,49</sup>. Baloxavir marboxil studies for influenza also show that treatment delay is critical — Ikematsu *et al.* report an 86% reduction in cases for post-exposure prophylaxis, Hayden *et al.* show a 33 hour reduction in the time to alleviation of symptoms for treatment within 24 hours and a reduction of 13 hours for treatment within 24-48 hours, and Kumar *et al.* report only 2.5 hours improvement for inpatient treatment.

Treatment delay	Result
Post-exposure prophylaxis	86% fewer cases <sup>50</sup>
<24 hours	-33 hours symptoms <sup>51</sup>
24-48 hours	-13 hours symptoms <sup>51</sup>
Inpatients	-2.5 hours to improvement <sup>52</sup>

**Table 2.** Studies of baloxavir marboxil for influenza show that early treatment is more effective.

Figure 14 shows a mixed-effects meta-regression for efficacy as a function of treatment delay in COVID-19 studies from 172 treatments, showing that efficacy declines rapidly with treatment delay. Early treatment is critical for COVID-19.





**Figure 14. Early treatment is more effective.** Meta-regression showing efficacy as a function of treatment delay in COVID-19 studies from 172 treatments.

#### Patient demographics

Details of the patient population including age and comorbidities may critically affect how well a treatment works. For example, many COVID-19 studies with relatively young low-comorbidity patients show all patients recovering quickly with or without treatment. In such cases, there is little room for an effective treatment to improve results, for example as in *López-Medina et al.*

#### SARS-CoV-2 variants

Efficacy may depend critically on the distribution of SARS-CoV-2 variants encountered by patients. Risk varies significantly across variants<sup>54</sup>, for example the Gamma variant shows significantly different characteristics<sup>55-58</sup>. Different mechanisms of action may be more or less effective depending on variants, for example the degree to which TMPRSS2 contributes to viral entry can differ across variants<sup>59,60</sup>.

#### Treatment regimen

Effectiveness may depend strongly on the dosage and treatment regimen.

#### Medication quality

The quality of medications may vary significantly between manufacturers and production batches, which may significantly affect efficacy and safety. *Williams et al.* analyze ivermectin from 11 different sources, showing highly variable antiparasitic efficacy across different manufacturers. *Xu et al.* analyze a treatment from two different manufacturers, showing 9 different impurities, with significantly different concentrations for each manufacturer.

#### Other treatments

The use of other treatments may significantly affect outcomes, including supplements, other medications, or other interventions such as prone positioning. Treatments may be synergistic<sup>63-79</sup>, therefore efficacy may depend strongly on combined treatments.

#### Effect measured

Across all studies there is a strong association between different outcomes, for example improved recovery is strongly associated with lower mortality. However, efficacy may differ depending on the effect measured, for example a treatment may be more effective against secondary complications and have minimal effect on viral clearance.

## Meta analysis

The distribution of studies will alter the outcome of a meta analysis. Consider a simplified example where everything is equal except for the treatment delay, and effectiveness decreases to zero or below with increasing delay. If there are many studies using very late treatment, the outcome may be negative, even though early treatment is very effective. All meta analyses combine heterogeneous studies, varying in population, variants, and potentially all factors above, and therefore may obscure efficacy by including studies where treatment is less effective. Generally, we expect the estimated effect size from meta analysis to be less than that for the optimal case. Looking at all studies is valuable for providing an overview of all research, important to avoid cherry-picking, and informative when a positive result is found despite combining less-optimal situations. However, the resulting estimate does not apply to specific cases such as early treatment in high-risk populations. While we present results for all studies, we also present treatment time and individual outcome analyses, which may be more informative for specific use cases.

## Pooled Effects

### Combining studies is required

For COVID-19, delay in clinical results translates into additional death and morbidity, as well as additional economic and societal damage. Combining the results of studies reporting different outcomes is required. There may be no mortality in a trial with low-risk patients, however a reduction in severity or improved viral clearance may translate into lower mortality in a high-risk population. Different studies may report lower severity, improved recovery, and lower mortality, and the significance may be very high when combining the results. *"The studies reported different outcomes"* is not a good reason for disregarding results. Pooling the results of studies reporting different outcomes allows us to use more of the available information. Logically we should, and do, use additional information when evaluating treatments—for example dose-response and treatment delay-response relationships provide additional evidence of efficacy that is considered when reviewing the evidence for a treatment.

### Specific outcome and pooled analyses

We present both specific outcome and pooled analyses. In order to combine the results of studies reporting different outcomes we use the most serious outcome reported in each study, based on the thesis that improvement in the most serious outcome provides comparable measures of efficacy for a treatment. A critical advantage of this approach is simplicity and transparency. There are many other ways to combine evidence for different outcomes, along with additional evidence such as dose-response relationships, however these increase complexity.


### Ethical and practical issues limit high-risk trials

Trials with high-risk patients may be restricted due to ethics for treatments that are known or expected to be effective, and they increase difficulty for recruiting. Using less severe outcomes as a proxy for more serious outcomes allows faster and safer collection of evidence.


### Validating pooled outcome analysis for COVID-19

For many COVID-19 treatments, a reduction in mortality logically follows from a reduction in hospitalization, which follows from a reduction in symptomatic cases, which follows from a reduction in PCR positivity. We can directly test this for COVID-19.


Analysis of the the association between different outcomes across studies from all 172 treatments we cover confirms the validity of pooled outcome analysis for COVID-19. Figure 15 shows that lower hospitalization is very strongly associated with lower mortality ( $p < 0.000000000001$ ). Similarly, Figure 16 shows that improved recovery is very strongly associated with lower mortality ( $p < 0.000000000001$ ). Considering the extremes, *Singh et al.* show an association between viral clearance and hospitalization or death, with  $p = 0.003$  after excluding one large outlier from a mutagenic treatment, and based on 44 RCTs including 52,384 patients. Figure 17 shows that improved viral clearance is strongly associated with fewer serious outcomes. The association is very similar to *Singh et al.*, with higher confidence due to the larger number of studies. As with *Singh et al.*, the confidence increases when excluding the outlier treatment, from  $p = 0.000000082$  to  $p = 0.000000033$ .



**Figure 15.** Lower hospitalization is associated with lower mortality, supporting pooled outcome analysis.



**Figure 16.** Improved recovery is associated with lower mortality, supporting pooled outcome analysis.




**Figure 15.** Improved viral clearance is associated with fewer serious outcomes, supporting pooled outcome analysis.

#### Pooled outcomes identify efficacy 5 months faster (7 months for RCTs)

Currently, 55 of the treatments we analyze show statistically significant efficacy or harm, defined as  $\geq 10\%$  decreased risk or  $>0\%$  increased risk from  $\geq 3$  studies. 88% of these have been confirmed with one or more specific outcomes, with a mean delay of 4.9 months. When restricting to RCTs only, 57% of treatments showing statistically significant efficacy/harm with pooled effects have been confirmed with one or more specific outcomes, with a mean delay of 7.3 months. Figure 18 shows when treatments were found effective during the pandemic. Pooled outcomes often resulted in earlier detection of efficacy.

## Time when COVID-19 studies showed efficacy

c19early.org  
July 2025



**Figure 18.** The time when studies showed that treatments were effective, defined as statistically significant improvement of  $\geq 10\%$  from  $\geq 3$  studies. Pooled results typically show efficacy earlier than specific outcome results. Results from all studies often shows efficacy much earlier than when restricting to RCTs. Results reflect conditions as used in trials to date, these depend on the population treated, treatment delay, and treatment regimen.

### Limitations

Pooled analysis could hide efficacy, for example a treatment that is beneficial for late stage patients but has no effect on viral clearance may show no efficacy if most studies only examine viral clearance. In practice, it is rare for a non-antiviral treatment to report viral clearance and to not report clinical outcomes; and in practice other sources of heterogeneity such as difference in treatment delay is more likely to hide efficacy.

### Summary

Analysis validates the use of pooled effects and shows significantly faster detection of efficacy on average. However, as with all meta analyses, it is important to review the different studies included. We also present individual outcome analyses, which may be more informative for specific use cases.

## Discussion

### Nasopharyngeal/oropharyngeal administration

Studies to date use a variety of administration methods to the respiratory tract, including nasal and oral sprays, nasal irrigation, oral rinses, and inhalation. Table 3 shows the relative efficacy for nasal, oral, and combined administration. Combined administration shows the best results, and nasal administration is more effective than oral. Precise efficacy depends on the details of administration, e.g., mucoadhesion and sprayability for sprays.

Nasal/oral administration to the respiratory tract	Improvement	Studies
Oral spray/rinse	38% [25-49%]	11
Nasal spray/rinse	58% [49-65%]	20
Nasal & oral	91% [74-97%]	7

**Table 3.** Respiratory tract administration efficacy. Relative efficacy of nasal, oral, and combined nasal/oral administration for treatments administered directly to the respiratory tract, based on studies for astodimer sodium, chlorhexidine, cetylpyridinium chloride, chlorpheniramine, iota-carrageenan, hydrogen peroxide, nitric oxide, povidone-iodine, plasma-activated water, alkalization, phthalocyanine, sodium bicarbonate, pHOXWELL, and sentinox. Results show random effects meta analysis for the most serious outcome reported for all prophylaxis and early treatment studies.

### Impact on the microbiome

Nasopharyngeal/oropharyngeal treatments may not be highly selective. In addition to inhibiting or disabling SARS-CoV-2, they may also be harmful to beneficial microbes, disrupting the natural microbiome in the oral cavity and nasal passages that have important protective and metabolic roles<sup>81</sup>. This may be especially important for prolonged use or overuse. Table 4 summarizes the potential for common nasopharyngeal/oropharyngeal treatments to affect the natural microbiome.

Treatment	Microbiome disruption potential	Notes
Iota-carrageenan	Low	Primarily antiviral, however extended use may mildly affect the microbiome
Nitric Oxide	Low to moderate	More selective towards pathogens, however excessive concentrations or prolonged use may disrupt the balance of bacteria
Alkalization	Moderate	Increases pH, negatively impacting beneficial microbes that thrive in a slightly acidic environment
Cetylpyridinium Chloride	Moderate	Quaternary ammonium broad-spectrum antiseptic that can disrupt beneficial and harmful bacteria
Phthalocyanine	Moderate to high	Photodynamic compound with antimicrobial activity, likely to affect the microbiome
Chlorhexidine	High	Potent antiseptic with broad activity, significantly disrupts the microbiome
Hydrogen Peroxide	High	Strong oxidizer, harming both beneficial and harmful microbes
Povidone-Iodine	High	Potent broad-spectrum antiseptic harmful to beneficial microbes


**Table 4.** Potential effect of treatments on the nasopharyngeal/oropharyngeal microbiome.

### Publication bias

Publishing is often biased towards positive results, however evidence suggests that there may be a negative bias for inexpensive treatments for COVID-19. Both negative and positive results are very important for COVID-19, media in many countries prioritizes negative results for inexpensive treatments (inverting the typical incentive for scientists that value media recognition), and there are many reports of difficulty publishing positive results<sup>82-85</sup>. For chlorpheniramine, there is currently not enough data to evaluate publication bias with high confidence.

One method to evaluate bias is to compare prospective vs. retrospective studies. Prospective studies are more likely to be published regardless of the result, while retrospective studies are more likely to exhibit bias. For example, researchers may perform preliminary analysis with minimal effort and the results may influence their decision to continue. Retrospective studies also provide more opportunities for the specifics of data extraction and adjustments to influence results.

Figure 19 shows a scatter plot of results for prospective and retrospective studies. The median effect size for retrospective studies is 54% improvement, compared to 74% for prospective studies, suggesting a potential bias towards publishing results showing lower efficacy.



**Figure 19.** Prospective vs. retrospective studies. The diamonds show the results of random effects meta-analysis.

### Conflicts of interest

Pharmaceutical drug trials often have conflicts of interest whereby sponsors or trial staff have a financial interest in the outcome being positive. Chlorpheniramine for COVID-19 lacks this because it is off-patent, has multiple manufacturers, and is very low cost. In contrast, most COVID-19 chlorpheniramine trials have been run by physicians on the front lines with the primary goal of finding the best methods to save human lives and minimize the collateral damage caused by COVID-19. While pharmaceutical companies are careful to run trials under optimal conditions (for example, restricting patients to those most likely to benefit, only including patients that can be treated soon after onset when necessary, and ensuring accurate dosing), not all chlorpheniramine trials represent the optimal conditions for efficacy.

### Limitations

Summary statistics from meta analysis necessarily lose information. As with all meta analyses, studies are heterogeneous, with differences in treatment delay, treatment regimen, patient demographics, variants, conflicts of interest, standard of care, and other factors. We provide analyses for specific outcomes and by treatment delay, and we aim to identify key characteristics in the forest plots and summaries. Results should be viewed in the context of study characteristics.

Some analyses classify treatment based on early or late administration, as done here, while others distinguish between mild, moderate, and severe cases. Viral load does not indicate degree of symptoms — for example patients may have a high viral load while being asymptomatic. With regard to treatments that have antiviral properties, timing of treatment is critical — late administration may be less helpful regardless of severity.

Details of treatment delay per patient is often not available. For example, a study may treat 90% of patients relatively early, but the events driving the outcome may come from 10% of patients treated very late. Our 5 day cutoff for early treatment may be too conservative, 5 days may be too late in many cases.



Comparison across treatments is confounded by differences in the studies performed, for example dose, variants, and conflicts of interest. Trials with conflicts of interest may use designs better suited to the preferred outcome.

In some cases, the most serious outcome has very few events, resulting in lower confidence results being used in pooled analysis, however the method is simpler and more transparent. This is less critical as the number of studies increases. Restriction to outcomes with sufficient power may be beneficial in pooled analysis and improve accuracy when there are few studies, however we maintain our pre-specified method to avoid any retrospective changes.

Studies show that combinations of treatments can be highly synergistic and may result in many times greater efficacy than individual treatments alone<sup>63-79</sup>. Therefore standard of care may be critical and benefits may diminish or disappear if standard of care does not include certain treatments.

This real-time analysis is constantly updated based on submissions. Accuracy benefits from widespread review and submission of updates and corrections from reviewers. Less popular treatments may receive fewer reviews.

No treatment or intervention is 100% available and effective for all current and future variants. Efficacy may vary significantly with different variants and within different populations. All treatments have potential side effects. Propensity to experience side effects may be predicted in advance by qualified physicians. We do not provide medical advice. Before taking any medication, consult a qualified physician who can compare all options, provide personalized advice, and provide details of risks and benefits based on individual medical history and situations.

### Reviews

*Ferrer et al.* present a review covering chlorpheniramine for COVID-19.

### Other studies

Additional preclinical or review papers suggesting potential benefits of chlorpheniramine for COVID-19 include<sup>89-91</sup>. We have not reviewed these studies in detail.

## Perspective

---


### Results compared with other treatments

SARS-CoV-2 infection and replication involves a complex interplay of 100+ host and viral proteins and other factors<sup>25-32</sup>, providing many therapeutic targets. Over 9,000 compounds have been predicted to reduce COVID-19 risk<sup>33</sup>, either by directly minimizing infection or replication, by supporting immune system function, or by minimizing secondary complications. Figure 20 shows an overview of the results for chlorpheniramine in the context of multiple COVID-19 treatments, and Figure 21 shows a plot of efficacy vs. cost for COVID-19 treatments.

## Efficacy in COVID-19 studies (pooled effects)

c19early.org

July 2025




**Figure 20.** Scatter plot showing results within the context of multiple COVID-19 treatments. Diamonds shows the results of random effects meta-analysis. 0.6% of 9,000+ proposed treatments show efficacy<sup>92</sup>.

## Efficacy vs. cost for COVID-19 treatments

c19early.org

July 2025



**Figure 21.** Efficacy vs. cost for COVID-19 treatments.

## Conclusion

SARS-CoV-2 infection typically starts in the upper respiratory tract. Progression may lead to cytokine storm, pneumonia, ARDS, neurological issues, organ failure, and death. Stopping replication in the upper respiratory tract, via early or prophylactic nasopharyngeal/oropharyngeal treatment, can avoid the consequences of progression to other tissues, and avoid the requirement for systemic treatments with greater potential for side effects.


Studies to date show that chlorpheniramine is an effective treatment for COVID-19. Significantly lower risk is seen for recovery. 2 studies (both from the same team/sponsor) show significant benefit. Meta analysis using the most serious outcome reported shows 56% [46-64%] lower risk. Results are similar for Randomized Controlled Trials and better for peer-reviewed studies.

Currently there is limited data, with only 806 patients and only 2 control events for the most serious outcome in trials to date. Studies to date are from only 2 different groups.

Chlorpheniramine may affect the natural microbiome, especially with prolonged use.


## Study Notes

### Sanchez-Gonzalez



Small RCT showing significantly improved recovery with intranasal chlorpheniramine maleate. Authors also perform an In Vitro study showing efficacy with a highly differentiated three-dimensional model of normal, human-derived tracheal/bronchial epithelial cells.


### Valerio-Pascua



RCT and retrospective study of chlorpheniramine nasal spray for COVID-19. The retrospective study included 660 outpatients showing fewer days with general COVID-19 symptoms, cough, anosmia, and ageusia compared to standard of care alone. The RCT results are listed separately<sup>93</sup>.

## Valerio-Pascua

## Chlorpheniramine ACCROS-I EARLY TREATMENT DB RCT



Is early treatment with chlorpheniramine beneficial for COVID-19?

Double-blind RCT 101 patients in Honduras (June 2021 - July 2022)

**Improved recovery ( $p=0.00018$ ) and lower PASC ( $p=0.001$ )**

Valerio-Pascua et al., Research Square, Oct 2022


c19early.org

RCT and retrospective study of chlorpheniramine nasal spray for COVID-19. The RCT included 101 outpatients showing significantly faster recovery with treatment. The retrospective study results are listed separately<sup>94</sup>. Long COVID results are from Valerio-Pascua (E) et al..

## Appendix 1. Methods and Data

We perform ongoing searches of PubMed, medRxiv, Europe PMC, ClinicalTrials.gov, The Cochrane Library, Google Scholar, Research Square, ScienceDirect, Oxford University Press, the reference lists of other studies and meta-analyses, and submissions to the site c19early.org. Search terms are chlorpheniramine and COVID-19 or SARS-CoV-2. Automated searches are performed twice daily, with all matches reviewed for inclusion. All studies regarding the use of chlorpheniramine for COVID-19 that report a comparison with a control group are included in the main analysis. Studies with major unexplained data issues, for example major outcome data that is impossible to be correct with no response from the authors, are excluded. This is a living analysis and is updated regularly.

We extracted effect sizes and associated data from all studies. If studies report multiple kinds of effects then the most serious outcome is used in pooled analysis, while other outcomes are included in the outcome specific analyses. For example, if effects for mortality and cases are reported then they are both used in specific outcome analyses, while mortality is used for pooled analysis. If symptomatic results are reported at multiple times, we use the latest time, for example if mortality results are provided at 14 days and 28 days, the results at 28 days have preference. Mortality alone is preferred over combined outcomes. Outcomes with zero events in both arms are not used, the next most serious outcome with one or more events is used. For example, in low-risk populations with no mortality, a reduction in mortality with treatment is not possible, however a reduction in hospitalization, for example, is still valuable. Clinical outcomes are considered more important than viral outcomes. When basically all patients recover in both treatment and control groups, preference for viral clearance and recovery is given to results mid-recovery where available. After most or all patients have recovered there is little or no room for an effective treatment to do better, however faster recovery is valuable. An IPD meta-analysis confirms that intermediate viral load reduction is more closely associated with



**Figure 22.** Mid-recovery results can more accurately reflect efficacy when almost all patients recover. Mateja et al. confirm that intermediate viral load results more accurately reflect hospitalization/death.

hospitalization/death than later viral load reduction<sup>96</sup>. If only individual symptom data is available, the most serious symptom has priority, for example difficulty breathing or low SpO<sub>2</sub> is more important than cough. When results provide an odds ratio, we compute the relative risk when possible, or convert to a relative risk according to *Zhang et al.* Reported confidence intervals and *p*-values are used when available, and adjusted values are used when provided. If multiple types of adjustments are reported propensity score matching and multivariable regression has preference over propensity score matching or weighting, which has preference over multivariable regression. Adjusted results have preference over unadjusted results for a more serious outcome when the adjustments significantly alter results. When needed, conversion between reported *p*-values and confidence intervals followed *Altman, Altman (B)*, and Fisher's exact test was used to calculate *p*-values for event data. If continuity correction for zero values is required, we use the reciprocal of the opposite arm with the sum of the correction factors equal to 1<sup>100</sup>. Results are expressed with RR < 1.0 favoring treatment, and using the risk of a negative outcome when applicable (for example, the risk of death rather than the risk of survival). If studies only report relative continuous values such as relative times, the ratio of the time for the treatment group versus the time for the control group is used. Calculations are done in Python (3.13.5) with *scipy* (1.16.0), *pythonmeta* (1.26), *numpy* (2.3.1), *statsmodels* (0.14.4), and *plotly* (6.2.0).

Forest plots are computed using *PythonMeta*<sup>101</sup> with the DerSimonian and Laird random effects model (the fixed effect assumption is not plausible in this case) and inverse variance weighting. Results are presented with 95% confidence intervals. Heterogeneity among studies was assessed using the *I*<sup>2</sup> statistic. Mixed-effects meta-regression results are computed with R (4.4.0) using the *metafor* (4.6-0) and *rms* (6.8-0) packages, and using the most serious sufficiently powered outcome. For all statistical tests, a *p*-value less than 0.05 was considered statistically significant. *Grobid* 0.8.2 is used to parse PDF documents.

We have classified studies as early treatment if most patients are not already at a severe stage at the time of treatment (for example based on oxygen status or lung involvement), and treatment started within 5 days of the onset of symptoms. If studies contain a mix of early treatment and late treatment patients, we consider the treatment time of patients contributing most to the events (for example, consider a study where most patients are treated early but late treatment patients are included, and all mortality events were observed with late treatment patients). We note that a shorter time may be preferable. Antivirals are typically only considered effective when used within a shorter timeframe, for example 0-36 or 0-48 hours for oseltamivir, with longer delays not being effective<sup>48,49</sup>.

We received no funding, this research is done in our spare time. We have no affiliations with any pharmaceutical companies or political parties.

A summary of study results is below. Please submit updates and corrections at <https://c19early.org/cpmmeta.html>.

## Early treatment

Effect extraction follows pre-specified rules as detailed above and gives priority to more serious outcomes. For pooled analyses, the first (most serious) outcome is used, which may differ from the effect a paper focuses on. Other outcomes are used in outcome specific analyses.

<i>Sanchez-Gonzalez</i> , 12/31/2022, Double Blind Randomized Controlled Trial, placebo-controlled, USA, peer-reviewed, mean age 44.5, 5 authors.	risk of hospitalization, 87.4% lower, RR 0.13, <i>p</i> = 0.08, treatment 0 of 32 (0.0%), control 2 of 13 (15.4%), NNT 6.5, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
<i>Valerio-Pascua</i> , 10/18/2022, retrospective, Honduras, preprint, 16 authors, study period June 2021 - July 2022, trial NCT05520944 (history) (ACCROS-II).	recovery time, 54.3% lower, relative time 0.46, <i>p</i> < 0.001, treatment mean 4.97 (±3.32) n=330, control mean 10.88 (±6.64) n=330.
<i>Valerio-Pascua (B)</i> , 10/18/2022, Double Blind Randomized Controlled Trial, placebo-controlled, Honduras, preprint, 16 authors, study period June 2021 - July 2022, trial NCT05449405 (history) (ACCROS-I).	<p>risk of no recovery, 61.4% lower, RR 0.39, <i>p</i> &lt; 0.001, treatment 61, control 40, all symptoms combined.</p> <p>risk of no recovery, 67.2% lower, RR 0.33, <i>p</i> = 0.15, treatment 3 of 61 (4.9%), control 6 of 40 (15.0%), NNT 9.9, day 7, anosmia.</p>

	risk of no recovery, 89.1% lower, RR 0.11, $p = 0.01$ , treatment 1 of 61 (1.6%), control 6 of 40 (15.0%), NNT 7.5, day 7, ageusia.
	risk of no recovery, 53.2% lower, RR 0.47, $p = 0.05$ , treatment 10 of 61 (16.4%), control 14 of 40 (35.0%), NNT 5.4, day 7, cough.
	risk of no recovery, 67.2% lower, RR 0.33, $p = 0.21$ , treatment 2 of 61 (3.3%), control 4 of 40 (10.0%), NNT 15, day 7, fatigue.
	risk of no recovery, 59.0% lower, RR 0.41, $p = 0.13$ , treatment 5 of 61 (8.2%), control 8 of 40 (20.0%), NNT 8.5, day 7, nasal congestion.
	relative PASC score, 73.5% better, RR 0.26, $p < 0.001$ , treatment 55, control 46, relative average composite PASC score.

## Supplementary Data

Supplementary Data

## Footnotes

- a. Viral infection and replication involves attachment, entry, uncoating and release, genome replication and transcription, translation and protein processing, assembly and budding, and release. Each step can be disrupted by therapeutics.

## References

- Ryu** et al., *Fibrin drives thromboinflammation and neuropathology in COVID-19*, *Nature*, doi:10.1038/s41586-024-07873-4.
- Dai** et al., *Neurological complications of COVID-19*, *QJM: An International Journal of Medicine*, doi:10.1093/qjmed/hcac272.
- Rong** et al., *Persistence of spike protein at the skull-meninges-brain axis may contribute to the neurological sequelae of COVID-19*, *Cell Host & Microbe*, doi:10.1016/j.chom.2024.11.007.
- Yang** et al., *SARS-CoV-2 infection causes dopaminergic neuron senescence*, *Cell Stem Cell*, doi:10.1016/j.stem.2023.12.012.
- Scardua-Silva** et al., *Microstructural brain abnormalities, fatigue, and cognitive dysfunction after mild COVID-19*, *Scientific Reports*, doi:10.1038/s41598-024-52005-7.
- Hampshire** et al., *Cognition and Memory after Covid-19 in a Large Community Sample*, *New England Journal of Medicine*, doi:10.1056/NEJMoa2311330.
- Duloquin** et al., *Is COVID-19 Infection a Multiorgan Disease? Focus on Extrapulmonary Involvement of SARS-CoV-2*, *Journal of Clinical Medicine*, doi:10.3390/jcm13051397.
- Sodagar** et al., *Pathological Features and Neuroinflammatory Mechanisms of SARS-CoV-2 in the Brain and Potential Therapeutic Approaches*, *Biomolecules*, doi:10.3390/biom12070971.
- Sagar** et al., *COVID-19-associated cerebral microbleeds in the general population*, *Brain Communications*, doi:10.1093/braincomms/fcae127.
- Verma** et al., *Persistent Neurological Deficits in Mouse PASC Reveal Antiviral Drug Limitations*, *bioRxiv*, doi:10.1101/2024.06.02.596989.
- Panagea** et al., *Neurocognitive Impairment in Long COVID: A Systematic Review*, *Archives of Clinical Neuropsychology*, doi:10.1093/arclin/aca042.
- Ariza** et al., *COVID-19: Unveiling the Neuropsychiatric Maze —From Acute to Long-Term Manifestations*, *Biomedicine*, doi:10.3390/biomedicine12061147.
- Vashisht** et al., *Neurological Complications of COVID-19: Unraveling the Pathophysiological Underpinnings and Therapeutic Implications*, *Viruses*, doi:10.3390/v16081183.
- Ahmad** et al., *Neurological Complications and Outcomes in Critically Ill Patients With COVID-19: Results From International Neurological Study Group From the COVID-19 Critical Care Consortium*, *The Neurohospitalist*, doi:10.1177/19418744241292487.
- Wang** et al., *SARS-CoV-2 membrane protein induces neurodegeneration via affecting Golgi-mitochondria interaction*, *Translational Neurodegeneration*, doi:10.1186/s40035-024-00458-1.



16. **Eberhardt** et al., SARS-CoV-2 infection triggers pro-atherogenic inflammatory responses in human coronary vessels, *Nature Cardiovascular Research*, doi:10.1038/s44161-023-00336-5.
17. **Van Tin** et al., Spike Protein of SARS-CoV-2 Activates Cardiac Fibrogenesis through NLRP3 Inflammasomes and NF- $\kappa$ B Signaling, *Cells*, doi:10.3390/cells13161331.
18. **Borka Balas** et al., COVID-19 and Cardiac Implications—Still a Mystery in Clinical Practice, *Reviews in Cardiovascular Medicine*, doi:10.31083/j.rcm2405125.
19. **ALTaweel** et al., An In-Depth Insight into Clinical, Cellular and Molecular Factors in COVID19-Associated Cardiovascular Ailments for Identifying Novel Disease Biomarkers, Drug Targets and Clinical Management Strategies, *Archives of Microbiology & Immunology*, doi:10.26502/ami.936500177.
20. **Saha** et al., COVID-19 beyond the lungs: Unraveling its vascular impact and cardiovascular complications—mechanisms and therapeutic implications, *Science Progress*, doi:10.1177/00368504251322069.
21. **Trender** et al., Changes in memory and cognition during the SARS-CoV-2 human challenge study, *eClinicalMedicine*, doi:10.1016/j.eclim.2024.102842.
22. **Wu** et al., SARS-CoV-2 replication in airway epithelia requires motile cilia and microvillar reprogramming, *Cell*, doi:10.1016/j.cell.2022.11.030.
23. **Demarco**, S., Shadowing SARS-CoV-2 Through Mucus and Cilia, *DDN*, [viewonline.drugdiscoverynews.com/hubfs/DDN%20Milestones/Shadowing%20SARS-CoV-2%20Through%20Mucus%20and%20Cilia.pdf](https://viewonline.drugdiscoverynews.com/hubfs/DDN%20Milestones/Shadowing%20SARS-CoV-2%20Through%20Mucus%20and%20Cilia.pdf).
24. **Lee** et al., ACE2 localizes to the respiratory cilia and is not increased by ACE inhibitors or ARBs, *Nature Communications*, doi:10.1038/s41467-020-19145-6.
25. **Dugied** et al., Multimodal SARS-CoV-2 interactome sketches the virus-host spatial organization, *Communications Biology*, doi:10.1038/s42003-025-07933-z.
26. **Malone** et al., Structures and functions of coronavirus replication–transcription complexes and their relevance for SARS-CoV-2 drug design, *Nature Reviews Molecular Cell Biology*, doi:10.1038/s41580-021-00432-z.
27. **Murigneux** et al., Proteomic analysis of SARS-CoV-2 particles unveils a key role of G3BP proteins in viral assembly, *Nature Communications*, doi:10.1038/s41467-024-44958-0.
28. **Lv** et al., Host proviral and antiviral factors for SARS-CoV-2, *Virus Genes*, doi:10.1007/s11262-021-01869-2.
29. **Lui** et al., Nsp1 facilitates SARS-CoV-2 replication through calcineurin-NFAT signaling, *Virology*, doi:10.1128/mbio.00392-24.
30. **Niarakis** et al., Drug-target identification in COVID-19 disease mechanisms using computational systems biology approaches, *Frontiers in Immunology*, doi:10.3389/fimmu.2023.1282859.
31. **Katiyar** et al., SARS-CoV-2 Assembly: Gaining Infectivity and Beyond, *Viruses*, doi:10.3390/v16111648.
32. **Wu (B)** et al., Decoding the genome of SARS-CoV-2: a pathway to drug development through translation inhibition, *RNA Biology*, doi:10.1080/15476286.2024.2433830.
33. **c19early.org**, [c19early.org/treatments.html](https://c19early.org/treatments.html).
34. **Sanchez-Gonzalez** et al., Intranasal Chlorpheniramine Maleate for the treatment of COVID-19: Translational and Clinical Evidence, *Medical Research Archives*, doi:10.18103/mra.v10i3.2752.
35. **Zeraatkar** et al., Consistency of covid-19 trial preprints with published reports and impact for decision making: retrospective review, *BMJ Medicine*, doi:10.1136/bmjmed-2022-0003091.
36. **Davidson** et al., No evidence of important difference in summary treatment effects between COVID-19 preprints and peer-reviewed publications: a meta-epidemiological study, *Journal of Clinical Epidemiology*, doi:10.1016/j.jclinepi.2023.08.011.
37. **Jadad** et al., *Randomized Controlled Trials: Questions, Answers, and Musings*, Second Edition, doi:10.1002/9780470691922.
38. **Götsche**, P., *Bias in double-blind trials*, Doctoral Thesis, University of Copenhagen, [www.scientificfreedom.dk/2023/05/16/bias-in-double-blind-trial-s-doctoral-thesis/](https://www.scientificfreedom.dk/2023/05/16/bias-in-double-blind-trial-s-doctoral-thesis/).
39. **Als-Nielsen** et al., Association of Funding and Conclusions in Randomized Drug Trials, *JAMA*, doi:10.1001/jama.290.7.921.
40. **c19early.org (B)**, [c19early.org/cpmsupp.html#fig\\_rctobs](https://c19early.org/cpmsupp.html#fig_rctobs).
41. **Concato** et al., *NEJM*, 342:1887-1892, doi:10.1056/NEJM200006223422507.
42. **Anglemeyer** et al., Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials, *Cochrane Database of Systematic Reviews* 2014, Issue 4, doi:10.1002/14651858.MR000034.pub2.
43. **c19early.org (C)**, [c19early.org/rctobs.html](https://c19early.org/rctobs.html).
44. **Lee (B)** et al., Analysis of Overall Level of Evidence Behind Infectious Diseases Society of America Practice Guidelines, *Arch Intern Med.*, 2011, 171:1, 18-22, doi:10.1001/archinternmed.2010.482.
45. **Deaton** et al., Understanding and misunderstanding randomized controlled trials, *Social Science & Medicine*, 210, doi:10.1016/j.socscimed.2017.12.005.
46. **Nichol** et al., Challenging issues in randomised controlled trials, *Injury*, 2010, doi: 10.1016/j.injury.2010.03.033, [www.injuryjournal.com/article/S0020-1383\(10\)00233-0/fulltext](http://www.injuryjournal.com/article/S0020-1383(10)00233-0/fulltext).
47. **Akash** et al., On a model-based approach to improve intranasal spray targeting for respiratory viral infections, *Frontiers in Drug Delivery*, doi:10.3389/fddev.2023.1164671.
48. **Treanor** et al., Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza: A Randomized Controlled Trial, *JAMA*, 2000, 283:8, 1016-1024, doi:10.1001/jama.283.8.1016.
49. **McLean** et al., Impact of Late Oseltamivir Treatment on Influenza Symptoms in the Outpatient Setting: Results of a Randomized Trial, *Open Forum Infect. Dis.* September 2015, 2:3, doi:10.1093/ofid/ofv100.



50. **Ikematsu** et al., Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts, *New England Journal of Medicine*, doi:10.1056/NEJMoa1915341.
51. **Hayden** et al., Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents, *New England Journal of Medicine*, doi:10.1056/NEJMoa1716197.
52. **Kumar** et al., Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial, *The Lancet Infectious Diseases*, doi:10.1016/S1473-3099(21)00469-2.
53. **López-Medina** et al., Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial, *JAMA*, doi:10.1001/jama.2021.3071.
54. **Korves** et al., SARS-CoV-2 Genetic Variants and Patient Factors Associated with Hospitalization Risk, *medRxiv*, doi:10.1101/2024.03.08.24303818.
55. **Faria** et al., Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil, *Science*, doi:10.1126/science.abh2644.
56. **Nonaka** et al., SARS-CoV-2 variant of concern P.1 (Gamma) infection in young and middle-aged patients admitted to the intensive care units of a single hospital in Salvador, Northeast Brazil, February 2021, *International Journal of Infectious Diseases*, doi:10.1016/j.ijid.2021.08.003.
57. **Karita** et al., Trajectory of viral load in a prospective population-based cohort with incident SARS-CoV-2 G614 infection, *medRxiv*, doi:10.1101/2021.08.27.21262754.
58. **Zavascki** et al., Advanced ventilatory support and mortality in hospitalized patients with COVID-19 caused by Gamma (P.1) variant of concern compared to other lineages: cohort study at a reference center in Brazil, *Research Square*, doi:10.21203/rs.3.rs-910467/v1.
59. **Willett** et al., The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism, *medRxiv*, doi:10.1101/2022.01.03.21268111.
60. **Peacock** et al., The SARS-CoV-2 variant, Omicron, shows rapid replication in human primary nasal epithelial cultures and efficiently uses the endosomal route of entry, *bioRxiv*, doi:10.1101/2021.12.31.474653.
61. **Williams, T.**, Not All Ivermectin Is Created Equal: Comparing The Quality of 11 Different Ivermectin Sources, *Do Your Own Research*, [doyourownresearch.substack.com/p/not-all-ivermectin-is-created-equal](https://doyourownresearch.substack.com/p/not-all-ivermectin-is-created-equal).
62. **Xu** et al., A study of impurities in the repurposed COVID-19 drug hydroxychloroquine sulfate by UHPLC-Q/TOF-MS and LC-SPE-NMR, *Rapid Communications in Mass Spectrometry*, doi:10.1002/rcm.9358.
63. **Jitobaom** et al., Favipiravir and Ivermectin Showed in Vitro Synergistic Antiviral Activity against SARS-CoV-2, *Research Square*, doi:10.21203/rs.3.rs-941811/v1.
64. **Jitobaom (B)** et al., Synergistic anti-SARS-CoV-2 activity of repurposed anti-parasitic drug combinations, *BMC Pharmacology and Toxicology*, doi:10.1186/s40360-022-00580-8.
65. **Jeffreys** et al., Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2, *International Journal of Antimicrobial Agents*, doi:10.1016/j.ijantimicag.2022.106542.
66. **Ostrov** et al., Highly Specific Sigma Receptor Ligands Exhibit Anti-Viral Properties in SARS-CoV-2 Infected Cells, *Pathogens*, doi:10.3390/pathogens10111514.
67. **Alsaïdi** et al., Griffithsin and Carrageenan Combination Results in Antiviral Synergy against SARS-CoV-1 and 2 in a Pseudoviral Model, *Marine Drugs*, doi:10.3390/md19080418.
68. **Andreani** et al., In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect, *Microbial Pathogenesis*, doi:10.1016/j.micpath.2020.104228.
69. **De Forni** et al., Synergistic drug combinations designed to fully suppress SARS-CoV-2 in the lung of COVID-19 patients, *PLoS ONE*, doi:10.1371/journal.pone.0276751.
70. **Wan** et al., Synergistic inhibition effects of andrographolide and baicalin on coronavirus mechanisms by downregulation of ACE2 protein level, *Scientific Reports*, doi:10.1038/s41598-024-54722-5.
71. **Said** et al., The effect of Nigella sativa and vitamin D3 supplementation on the clinical outcome in COVID-19 patients: A randomized controlled clinical trial, *Frontiers in Pharmacology*, doi:10.3389/fphar.2022.1011522.
72. **Fiaschi** et al., In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants, *Viruses*, doi:10.3390/v16020168.
73. **Xing** et al., Published anti-SARS-CoV-2 in vitro hits share common mechanisms of action that synergize with antivirals, *Briefings in Bioinformatics*, doi:10.1093/bib/bbab249.
74. **Chen** et al., Synergistic Inhibition of SARS-CoV-2 Replication Using Disulfiram/Ebselen and Remdesivir, *ACS Pharmacology & Translational Science*, doi:10.1021/acspstsci.1c00022.
75. **Hempel** et al., Synergistic inhibition of SARS-CoV-2 cell entry by otamixaban and covalent protease inhibitors: pre-clinical assessment of pharmacological and molecular properties, *Chemical Science*, doi:10.1039/D1SC01494C.
76. **Schultz** et al., Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2, *Nature*, doi:10.1038/s41586-022-04482-x.
77. **Ohashi** et al., Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment, *iScience*, doi:10.1016/j.isci.2021.102367.
78. **Al Krad** et al., The protease inhibitor Nirmatrelvir synergizes with inhibitors of GRP78 to suppress SARS-CoV-2 replication, *bioRxiv*, doi:10.1101/2025.03.09.642200.
79. **Thairu** et al., A Comparison of Ivermectin and Non Ivermectin Based Regimen for COVID-19 in Abuja: Effects on Virus Clearance, Days-to-discharge and Mortality, *Journal of Pharmaceutical Research International*, doi:10.9734/jpri/2022/v34i44A36328.

80. **Singh** et al., The relationship between viral clearance rates and disease progression in early symptomatic COVID-19: a systematic review and meta-regression analysis, *Journal of Antimicrobial Chemotherapy*, doi:10.1093/jac/dkac045.
81. **Brookes** et al., Mouthwash Effects on the Oral Microbiome: Are They Good, Bad, or Balanced?, *International Dental Journal*, doi:10.1016/j.identj.2023.08.010.
82. **Meneguesso**, A., Médica defende tratamento precoce da Covid-19, [www.youtube.com/watch?v=X5FCrIm\\_19U](https://www.youtube.com/watch?v=X5FCrIm_19U).
83. **Boulware**, D., Comments regarding paper rejection, [twitter.com/boulware\\_dr/status/1311331372884205570](https://twitter.com/boulware_dr/status/1311331372884205570).
84. **Meeus**, G., Online Comment, [twitter.com/gertmeeus\\_MD/status/1386636373889781761](https://twitter.com/gertmeeus_MD/status/1386636373889781761).
85. **twitter.com**, [twitter.com/KashPrime/status/1768487878454124914](https://twitter.com/KashPrime/status/1768487878454124914).
86. **Ferrer** et al., Intranasal Chlorpheniramine for Early Symptomatic Treatment of COVID-19 and the Impact on Long-COVID, *Cureus*, doi:10.7759/cureus.82736.
87. **Valerio-Pascua** et al., Chlorpheniramine Intranasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: The ACCROS Trials, *Research Square*, doi:10.21203/rs.3.rs-2167465/v1.
88. **Valerio-Pascua (B)** et al., Chlorpheniramine Intranasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: The ACCROS Trials, *Research Square*, doi:10.21203/rs.3.rs-2167465/v1.
89. **Black**, S., Molecular Modeling and Preliminary Clinical Data Suggesting Antiviral Activity for Chlorpheniramine (Chlorphenamine) Against COVID-19, *Cureus*, doi:10.7759/cureus.20980.
90. **Loucera** et al., Drug repurposing for COVID-19 using machine learning and mechanistic models of signal transduction circuits related to SARS-CoV-2 infection, *Signal Transduction and Targeted Therapy*, doi:10.1038/s41392-020-00417-y.
91. **Negru** et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, *Biomedicine & Pharmacotherapy*, doi:10.1016/j.biopha.2022.113432.
92. **c19early.org (D)**, [c19early.org/timeline.html](https://c19early.org/timeline.html).
93. **Valerio-Pascua (C)** et al., Chlorpheniramine Intranasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: The ACCROS Trials, *Research Square*, doi:10.21203/rs.3.rs-2167465/v1.
94. **Valerio-Pascua (D)** et al., Chlorpheniramine Intranasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: The ACCROS Trials, *Research Square*, doi:10.21203/rs.3.rs-2167465/v1.
95. **Valerio-Pascua (E)** et al., Mitigating the risks of post-acute sequelae of SARS-CoV-2 infection (PASC) with intranasal chlorpheniramine: perspectives from the ACCROS studies, *BMC Infectious Diseases*, doi:10.1186/s12879-024-10211-8.
96. **Mateja** et al., The choice of viral load endpoint in early phase trials of COVID-19 treatments aiming to reduce 28-day hospitalization and/or death, *The Journal of Infectious Diseases*, doi:10.1093/infdis/jiaf282.
97. **Zhang** et al., What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes, *JAMA*, 80:19, 1690, doi:10.1001/jama.280.19.1690.
98. **Altman**, D., How to obtain the P value from a confidence interval, *BMJ*, doi:10.1136/bmj.d2304.
99. **Altman (B)** et al., How to obtain the confidence interval from a P value, *BMJ*, doi:10.1136/bmj.d2090.
100. **Sweeting** et al., What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data, *Statistics in Medicine*, doi:10.1002/sim.1761.
101. **Deng**, H., PyMeta, Python module for meta-analysis, [www.pymeta.com/](http://www.pymeta.com/).